Novartis Invests in Singapore Biopharmaceutical Facility to Meet Growing Demand

Novartis has initiated the development of its biopharmaceutical manufacturing plant located in Singapore, investing just over $250 million to cater to the rising demand in the Asian market. 

This development will generate 100 new positions and has aims to progress manufacturing therapeutic antibody medications. 

The expansion will integrate digital and automation technologies to boost efficiency and productivity and provide training to the current workforce. 

Steffen Lang, the chief of operations at Novartis, stated, “Biotherapeutics now account for almost one-half of all recent drug approvals and have enormous potential to address unmet needs of patients across a wide range of diseases.” 

Lang went on to add, “To meet this increasing demand for biologics, the Novartis early-stage biologics portfolio has been growing significantly in terms of capacities and investment.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.